Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1501 to 1515 of 1541 results for do not do recommendations

  1. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

  2. Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS

    Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.

  3. New AI tools could help save lives by spotting warning signs of bowel cancer earlier

    Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.

  4. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

  5. Shaping the future of global health technology assessment

    Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.

  6. Should NICE's cost-effectiveness thresholds change?

    We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.

  7. Same time decisions on licensing and value - what pharmaceutical companies need to know

    Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.

  8. Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes

    Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.

  9. Biggest shake-up in type 2 diabetes care in a decade announced

    Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.

  10. Final draft guidance finds benefits of 2 Alzheimer's treatments remain too small to justify the additional costs to the NHS

    The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.

  11. 'Artificial pancreas' transforming the lives of thousands of children and young people with type 1 diabetes

    The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.

  12. New guideline will help cut falls and related hospital admissions for older and at-risk people

    Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.

  13. New life-changing treatment option recommended for type of rare epilepsy

    This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.

  14. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.

  15. NICE recommends 8 digitally enabled therapies to treat depression and anxiety

    Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.